Table 2. Direct costs used for lymphatic filariasis with lower and upper limits [between brackets].

LF Sequela	WHO region	Annual Direct Costs2 (int US$)	Patients Seeking Treatment	Patients that have ADLA	Source
ADLA1 Lymphedema	WHO AFRO3	0.36 [0.6–1.25]	65% [55% - 70%]	95% [90–95%]	[40]
	WHO SEARO4	5.60 [0.93–19.43]
	WHO WPRO5	19.60 [3.27–68.1]
	WHO AMRO6	6.009 [1.0–20.82]
	WHO EMRO7	0.36 [0.06–1.25]
	All GPELF countries8	6.00 [1.0–20.82]
	India11	(same as SEARO)	85% [65% - 98%]	95% [90–95%]	[40,43,44,80]
ADLA Hydrocele	WHO AFRO	0.18 [0.3–0.62]	65% [55% - 70%]	70% [45% - 90%]	[40]
	WHO SEARO	2.80 [0.47–9.72]
	WHO WPRO	9.80 [1.63–34.01]
	WHO AMRO	0.18 [0.03–0.62]
	WHO EMRO	0.18 [0.03–0.62]
	All GPELF countries	3.00 [0.50–10.41]
	India11	(same as SEARO)	85% [65% - 98%]	70% [45% - 90%]	[40,43,44,80]
Chronic Lymphedema	All regions	4.3 [0.85–15.0]	50% [30–55%]	-	[40]
	India11		65% [49–74%]	-	[40,43,80]
Chronic Hydrocele 10	All regions	2.9 [0.55–10.05]	40% [20–50%]	-	[40]
	India11		60% [49–74%]	-

1. ADLA—acute dermatolymphangioadenitis.

2. Based on an average of two ADLA episodes a year for hydrocele and four ADLA episodes a year for lymphedema [40].

3. WHO AFRO—World Health Organization African Region.

4. WHO SEARO—World Health Organization Region South-East Asia.

5. WHO WPRO—World Health Organization Western Pacific Region.

6. WHO AMRO—World Health Organization Americas Region.

7. WHO EMRO—World Health Organization Eastern Mediterranean Region.

8. GPELF–Global Programme to Eliminate Lymphatic Filariasis.

9. Since the region-specific estimate was not mentioned, the global average was used [40].

10. Hydrocelectomy already included in the chronic cost of hydrocele.

11. Different estimates were used for India due to more primary data available suggesting estimates differ from other regions. [40].